Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Vorinostat × 90 days × Clear all

Phase

Status

Sponsor Class

OTHER 9 NIH 5 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 305 Carboplatin 230 Cisplatin 162 Paclitaxel 155 Gemcitabine 145 Pemetrexed 126 Bevacizumab 124 Docetaxel 101 Nivolumab 86 Cyclophosphamide 86 atezolizumab 80 Oxaliplatin 80 durvalumab 78 Capecitabine 78 Fluorouracil 73 Fulvestrant 72 Dexamethasone 70 130-nm albumin-bound paclitaxel 67 Injections 64 Leucovorin 58 Rituximab 56 Cetuximab 55 fludarabine 54 Prednisone 51 venetoclax 47 Lenalidomide 47 Trastuzumab 45 Irinotecan 44 Doxorubicin 43 Letrozole 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00875056 2026-01-30

MK-0683-103

Merck Sharp & Dohme LLC

Phase 2 Completed

56 enrolled 14 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡